Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
011000.KS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
NA
vs NA
Q1.23
N/A
-170.00
vs NA
Q2.23
N/A
-171.00
vs NA
Q3.23
N/A
NA
vs NA
Q4.23
N/A
NA
vs NA
Q1.24
N/A
NA
vs -170.00
Q2.24
N/A
NA
vs -171.00
Q3.24
N/A
NA
vs NA
Q4.24
N/A
NA
vs NA
Q1.25
N/A
NA
vs NA
Sales Growth
YoY
Current
Estimates
Q4.22
-3%
9.8B vs 10.2B
Q1.23
-38%
7.4B vs 11.9B
Q2.23
-42%
8.3B vs 14.4B
Q3.23
-7%
11.7B vs 12.5B
Q4.23
+30%
12.8B vs 9.8B
Q1.24
-5%
7B vs 7.4B
Q2.24
+12%
9.3B vs 8.3B
Q3.24
-24%
8.9B vs 11.7B
Q4.24
-18%
10.5B vs 12.8B
Q1.25
+21%
8.5B vs 7B
Return on Equity
QoQ
Q2.23
-8%
-0.08
vs -0.07
Q3.23
-7%
-0.07
vs -0.08
Q4.23
-36%
-0.36
vs -0.07
Q1.24
-8%
-0.08
vs -0.36
Q2.24
-12%
-0.12
vs -0.08
Q3.24
-12%
-0.12
vs -0.12
Q4.24
-18%
-0.18
vs -0.12
Q1.25
-12%
-0.12
vs -0.18
Institutionnal Ownership
Relative Strength
011000.KS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the development and contract manufacturing of gene-based-biomedicines. Its products comprise GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company also develops GLS-3000 and GLS-5310 for the treatment of SARS-CoV-2; GLS-5100 to treat VZV-Shingles; and GLS-5140 for the treatment of SFTS. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C, as well as GLS-6100 that is in pre-clinical stage for hepatitis C. Further, the company, through its subsidiary, VGXI, Inc., engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.
KSC
10.00Â ( 0.41%)
Relative Strenght
Volume Buzz
-93%
Earning Acce
No
Dist 52w H.
48%Forecast
No Data Available
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How 011000.KS compares to sector?